Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037635 | 1.00 | HRH3 (0.52) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL13584955 | 0.87 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL3448485 | 0.87 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL3180028 | 0.87 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL6943424 | 0.87 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL3448482 | 0.87 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL29380816 | 0.87 | HRH3 (0.54) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| Hydrochloric Acid SCHEMBL25363703 | 0.86 | HRH3 (0.53) | HRH3SLC6A4SLC6A2SLC6A3HRH1 | |
| SCHEMBL951361 | 0.85 | HRH3 (0.50) | HRH3SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3961763 | 0.85 | HRH3 (0.50) | HRH3SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7473760-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473760-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | HRH3 1495/4885SLC6A4 4706/4885SLC6A2 4401/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | HRH3 3940/4885SLC6A4 1920/4885SLC6A2 1320/4885 |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | HRH3 1926/4885SLC6A4 3429/4885SLC6A2 1559/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | HRH3 1495/4885SLC6A4 4706/4885SLC6A2 4401/4885 |
| US-20080234289-A1 | Melanocortin Receptor-Specific Compounds | MC1R, MC3R, MC5R | HRH3 129/4885SLC6A4 518/4885SLC6A2 351/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | HRH3 4203/4885SLC6A4 3934/4885SLC6A2 3756/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | HRH3 1495/4885SLC6A4 4706/4885SLC6A2 4401/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | HRH3 4203/4885SLC6A4 3934/4885SLC6A2 3756/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | HRH3 3940/4885SLC6A4 1920/4885SLC6A2 1320/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | HRH3 3940/4885SLC6A4 1920/4885SLC6A2 1320/4885 |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | HRH3 4536/4885SLC6A4 4349/4885SLC6A2 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.